All research
Human randomized trial / 2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Study overview
A 72-week randomized trial enrolled 2,539 adults with obesity or overweight and a weight-related complication, excluding diabetes. Tirzepatide groups had greater average weight reduction than placebo.
Results are specific to the study. This is an editorial summary, not personal treatment advice.
Study limitations
Results apply to the enrolled population and monitored trial conditions. Gastrointestinal adverse events and treatment discontinuations matter alongside efficacy; these findings do not establish the quality or safety of unregulated products.
About this summary
This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.